- Dahiya, Rajvir;
- Arichi, N;
- Mitsui, Y;
- Hiraki, M;
- Nakamura, S;
- Hiraoka, T;
- Sumura, M;
- Hirata, H;
- Tanaka, Y;
- Yasumoto, H
In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell